Showing 4 posts of 4 posts found.


Incyte’s ruxolitinib cream formulations look strong in Phase 3 atopic dermatitis

April 7, 2020
Manufacturing and Production, Research and Development Incyte, atopic dermatitis, ruxolitinib

Incyte has lifted the curtain on promising new Phase 3 data for its 0.75% and 1.5% twice daily cream formulations …

Jakavi image

Novartis blood cancer drug given EU nod

March 17, 2015
Sales and Marketing Cancer, EU, Jakavi, Novartis, oncology, polycythemia vera, ruxolitinib

Novartis’ blood cancer drug Jakavi has been given the green light in Europe to treat adult patients with polycythemia vera …

Novartis image

Novartis earns EMA and FDA nods for Jakavi and Bexsero

January 26, 2015
Sales and Marketing Bexsero, Cancer, EU, FDA, Jakavi, Novartis, US, meningitis, ruxolitinib

Novartis has secured the regulatory go-ahead for two of its drugs, after the EMA recommended Jakavi for a rare blood …

Novartis plans Q2 filing for blood cancer drug

March 17, 2011
Sales and Marketing COMFORT-II trial, INC424, Incyte, JAK, Janus kinase inhibitor, Novartis, blood cancer, cancer drug, myelofibrosis, ruxolitinib

Novartis will file ruxolitinib for worldwide regulatory approval in the second quarter after the cancer drug met its primary endpoint …

Latest content